Needham & Company analyst Chad Messer reiterated a Buy rating and boosted his price target on Esperion Therapeutics (NASDAQ: ESPR) to $130.00 (from $104.00), citing multiple value-creating events through year-end.

Esperion has submitted briefing documents to the FDA and expects to be able to hold their end-of-phase II meeting for ETC-1002 in the first half of 3Q:15. In addition to this critical meeting, we see several other potential value creating events for Esperion through YE:15. We reiterate our Buy rating and raise our price target to $130. Since we last assigned a price target to ESPR shares the company has reported better than expected data in combination with statins and has raised $200 million to accelerate a cardiovascular outcomes trial

For an analyst ratings summary and ratings history on Esperion Therapeutics click here. For more ratings news on Esperion Therapeutics click here.

Shares of Esperion Therapeutics closed at $99.98 yesterday.